American Academy of Dermatology

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

The oral S1P receptor modulator has promise to break new ground for disease modification.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.

Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.

Onychomycosis—fungal infection of the nail—is a common medical problem. Treatments are widely available, but relapse is common.

In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.

Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.

Recommendations for acne treatment drawn from AAD position paper and presentations.

Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.

The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.

Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.

The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.

A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.

Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.

Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.

This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.

Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.

Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.

The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.

Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.

Though there are few treatments for pemphigus vulgaris, a rare disease, the Believe-PV trial of PRN1008 raises the possibility of a new, better option.